| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 543 | 2021 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 387 | 2021 |
| Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1 P Bastard, E Orlova, L Sozaeva, R Lévy, A James, MM Schmitt, S Ochoa, ... Journal of Experimental Medicine 218 (7), 2021 | 269 | 2021 |
| Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19 MGP van der Wijst, SE Vazquez, GC Hartoularos, P Bastard, T Grant, ... Science translational medicine 13 (612), eabh2624, 2021 | 199 | 2021 |
| Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine P Bastard, E Michailidis, HH Hoffmann, M Chbihi, T Le Voyer, J Rosain, ... Journal of Experimental Medicine 218 (4), e20202486, 2021 | 183 | 2021 |
| The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ... Proceedings of the National Academy of Sciences 119 (21), 2022 | 164 | 2022 |
| Inborn errors of OAS–RNase L in SARS-CoV-2–related multisystem inflammatory syndrome in children D Lee, J Le Pen, A Yatim, B Dong, Y Aquino, M Ogishi, R Pescarmona, ... Science 379 (6632), eabo3627, 2022 | 116 | 2022 |
| Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort R Carapito, R Li, J Helms, C Carapito, S Gujja, V Rolli, R Guimaraes, ... Science translational medicine 14 (628), eabj7521, 2022 | 109 | 2022 |
| Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital A Chauvineau-Grenier, P Bastard, A Servajean, A Gervais, J Rosain, ... Journal of clinical immunology 42 (3), 459-470, 2022 | 82 | 2022 |
| Autoantibodies against type I IFNs in patients with critical influenza pneumonia Q Zhang, A Pizzorno, L Miorin, P Bastard, A Gervais, T Le Voyer, L Bizien, ... Journal of Experimental Medicine 219 (11), e20220514, 2022 | 78 | 2022 |
| Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma SE Vazquez, P Bastard, K Kelly, A Gervais, PJ Norris, LJ Dumont, ... Journal of clinical immunology 41 (6), 1169-1171, 2021 | 67 | 2021 |
| Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α A Mathian, P Breillat, K Dorgham, P Bastard, C Charre, R Lhote, ... Annals of the rheumatic diseases 81 (12), 1695-1703, 2022 | 63 | 2022 |
| Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 D Matuozzo, E Talouarn, A Marchal, P Zhang, J Manry, Y Seeleuthner, ... Genome medicine 15 (1), 22, 2023 | 61 | 2023 |
| Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs P Bastard, SE Vazquez, J Liu, MT Laurie, CY Wang, A Gervais, ... Science immunology 8 (90), eabp8966, 2023 | 57 | 2023 |
| Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency T Le Voyer, AV Parent, X Liu, A Cederholm, A Gervais, J Rosain, ... Nature 623 (7988), 803-813, 2023 | 57 | 2023 |
| Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in∼ 40% of patients A Gervais, F Rovida, MA Avanzini, S Croce, A Marchal, SC Lin, A Ferrari, ... Journal of Experimental Medicine 220 (9), e20230661, 2023 | 50 | 2023 |
| A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes P Bastard, KC Hsiao, Q Zhang, J Choin, E Best, J Chen, A Gervais, ... Journal of Experimental Medicine 219 (6), e20220028, 2022 | 47 | 2022 |
| Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination A Sokal, P Bastard, P Chappert, G Barba-Spaeth, S Fourati, ... Journal of Experimental Medicine 220 (1), e20220258, 2022 | 31 | 2022 |
| Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19: Anti-IFN antibodies in critical … MGP van der Wijst, SE Vazquez, GC Hartoularos, P Bastard, T Grant, ... BioRxiv, 2021 | 28 | 2021 |
| Auto-antibodies against type I IFNs in> 10% of critically ill COVID-19 patients: a prospective multicentre study R Arrestier, P Bastard, T Belmondo, G Voiriot, T Urbina, CE Luyt, ... Annals of Intensive Care 12 (1), 121, 2022 | 26 | 2022 |